<DOC>
	<DOCNO>NCT00140218</DOCNO>
	<brief_summary>The hypothesis study treatment R ( + ) pramipexole 30 mg/day alter slope decline ALS functional rating scale course 6 month . ALS patient early stage disease observe 3 month enrollment treat drug 6 month .</brief_summary>
	<brief_title>R ( + ) Pramipexole Early Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>This futility design Phase II study use ALS-FRSr primary variable monitor progression disease patient early ALS . The drug test R ( + ) pramipexole , antioxidant concentrate brain mitochondrion . R ( + ) PPX administer 30 mg/day 6 month , follow 3 month lead-in period without drug therapy . For purpose study , futility define failure decrease slope ALS-FRSr decline less 40 % .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>establish diagnosis ALS FVC &gt; 60 % predict ventilated difficulty swallow ambulatory ( use assistance device ) ALS duration &gt; 3 year advanced ALS survival predict &lt; 6 month dementia ( MMSE &lt; 22 ) prior exposure R ( + ) pramipexole orthostatic hypotension &gt; 30 mmHg history psychosis hallucination abnormal baseline safety lab value</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>pramipexole</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>neuroprotection</keyword>
</DOC>